AREVA Med Inaugurates Second Lead-212 Production Facility
(Thomson Reuters ONE) -
Harry LaRosiliere, mayor of Plano; Patrick Bourdet, AREVA Med CEO photo credit:
Jim Herndon
PLANO, Texas, April 13, 2016 (GLOBE NEWSWIRE) -- AREVA Med has launched
operations at its second high-purity lead-212 ((212)Pb) production facility
located in Plano, Texas. Known as the DDPU (Domestic Distribution and
Purification Unit), this facility was officially opened today in the presence of
local elected officials, AREVA Med Scientific Advisory Committee, as well as
AREVA Group and AREVA Med executives and teams from both the U.S. and France.
A photo accompanying this release is available
at http://www.globenewswire.com/NewsRoom/AttachmentNg/bccb050d-dfc0-46c3-9964-
a31bc2f553f4
Thanks to its unique characteristics, lead-212 is used in targeted alpha therapy
(TAT), in an increasing number of promising and innovative studies to target
cancer cells, while limiting the impact on nearby healthy cells.
In a centralized modular plant, the DDPU will hold all AREVA Med's U.S.
activities and those of its subsidiary Macrocyclics, the global leader in the
design and manufacturing of chelating agents for nuclear medicine. With brand
new equipment, this state-of-the-art facility is a unique opportunity for AREVA
Med to expand the range and increase the quality of products and services for
its American partners and customers. Thanks to this increased production
capacities, AREVA Med will accelerate the development of innovative Targeted
Alpha Therapies using lead-212 to combat cancer.
Harry LaRosiliere, the mayor of Plano, declared: "It is always a great day when
we can welcome to the City of Plano a U.S. Headquarters and international
company such as AREVA Med, which does invaluable work in the field of cancer
research. We look forward to their success and future expansion as they continue
to develop innovative cancer therapies."
Patrick Bourdet, AREVA Med's CEO added: "Our new modular and unique U.S. plant
will allow us to quickly expand our cancer therapy pipeline and increase
collaboration within the entire continent."
More information at www.arevamed.com, (at)AREVAmed
More about AREVA Med
AREVA Med is the AREVA Group medical subsidiary formed in 2009 to develop new
therapies to fight cancer. AREVA Med has developed a unique process to extract
lead-212 ((212)Pb), a rare metal used in targeted alpha therapy (TAT), a novel
approach which targets and destroys cancer cells, while limiting the impact on
nearby healthy cells. AREVA Med collaborates with world-renowned scientific
partners, and formed a strategic global alliance with Roche in 2012, to create a
new advanced alpha radioimmunotherapy platform.
Press Contacts
AREVA Med
Alison Tise
(301) 841-1673
Alison.Tise(at)areva.com
(at)AREVAmed
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: AREVA Med via GlobeNewswire
[HUG#2003419]
Datum: 13.04.2016 - 21:36 Uhr
Sprache: Deutsch
News-ID 463901
Anzahl Zeichen: 3610
contact information:
Town:
Plano
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 222 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"AREVA Med Inaugurates Second Lead-212 Production Facility"
steht unter der journalistisch-redaktionellen Verantwortung von
AREVA Med (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
